This segment focuses on the research, development, and clinical evaluation of milademetan, an oral small molecule inhibitor of MDM2. The primary research and development activities involve Phase 3 clinical trials for liposarcoma, Phase II trials for solid tumors and intimal sarcoma, and preclinical studies for other cancers. The technology utilized is small molecule drug development, with a focus on targeting oncogenic drivers. The therapeutic area is oncology, specifically targeting cancers where MDM2 is oncogenic. The patient impact is aimed at providing new treatment options for patients with limited treatment choices. Market positioning is as a late-stage precision oncology company. Future opportunities include expanding the use of milademetan in additional cancer types and combination therapies. Regulatory and clinical aspects include navigating FDA approval processes and conducting clinical trials. Partnerships include collaborations with Roche for clinical trials.

This segment focuses on the preclinical development of RAD52 inhibitors for various cancers. Research and development activities include preclinical studies to evaluate the efficacy and safety of RAD52 inhibitors in tumors, including breast, ovarian, pancreatic, and prostate cancers. The technologies and methodologies used involve molecular biology and preclinical drug development. The therapeutic areas covered are multiple cancers. The patient impact is aimed at providing new treatment options for patients with these cancers. Market positioning is as a company developing therapies that target oncogenic drivers. Future opportunities include advancing RAD52 inhibitors into clinical trials. Regulatory and clinical aspects include preparing for FDA approval and clinical trial design. This segment is currently in the preclinical stage.